A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Metastatic Hormone-sensitive Prostate Cancer Clinical Trial

Official title:

A Multi-arm, Multi-stage, Randomized Phase II/III Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03879122
• Other study ID #: CA209-9HX
• Status: Active, not recruiting
• Phase: Phase 2/Phase 3
• Start date: February 11, 2019
• Est. completion date: December 31, 2024

Study information

• Verified date: October 2022
• Source: Spanish Oncology Genito-Urinary Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Metastatic prostate cancer is an incurable disease that typically spreads beyond the prostate. The standard of care is to systemically treat the disease with androgen deprivation therapy (ADT). However, the disease progresses in virtually all patients to the state of castration resistant prostate cancer (CRPC), with a median time to progression of 24 months. Patients with high volume disease (with either visceral metastasis and/or bone metastasis) exhibit a worse prognosis, with a median clinical progression of 14 months. Recently, the CHAARTED and STAMPEDE studies demonstrated that the combination of Docetaxel (chemotherapy) and ADT delayed the clinical progression and improved the survival a median of 14 months (17 for high volume patients). Nevertheless, the prognosis of patients with high volume metastatic disease continues to be poor. Meanwhile the immunotherapy, the use of antibodies that recognize tumoral cells and promote the immune system activity against the cancer, has emerged as a very useful option in many cancers. Among others, the antibodies Nivolumab and Ipilimumab have been approved for the treatment of multiple types of cancer. In this context, SOGUG (Spanish Oncology Genitourinary Group) has designed this new study "PROSTRATEGY" with the objective of evaluating whether the addition of immunotherapy to chemotherapy and ADT improves the prognosis and survival of patients with high volume metastatic hormone-sensitive prostate cancer.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 135
• Est. completion date: December 31, 2024
• Est. primary completion date: July 31, 2023
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients must be at least 18 years of age

2. Signed and dated written informed consent, obtained before the performance of any protocol-related procedure.

3. Histological or cytological diagnosis of prostate cancer with an elevated PSA level and radiologic evidence of metastatic disease.

4. ECOG performance-status score of 0, 1, or 2. Patients with a score of 2 are eligible if the decrement in functioning was due to prostate cancer.

5. Metastatic disease that has spread beyond the prostate or relapsed after local therapy, documented by body CT scan and/or bone scan, according to PCWG 3 criteria, with high volume according to criteria used in the CHAARTED study.

6. Radiological and scintigraphic studies to identify initial evaluable disease should be

done as follows:

• If ADT has not been initiated, CT scans and bone scan must be obtained within 6 weeks prior to the start of ADT.
• If all required imaging had not been completed prior to starting ADT, any additional scan must be obtained after starting androgen deprivation but prior to randomization and the initiation of docetaxel (It is assumed that the scans of patients with high volume disease would not normalize in less than 120 days to the point that a patient would go from "high volume" to "low volume").

7. Measurable or evaluable disease according to the PWGC 3.

8. Patients who started ADT for metastatic disease are eligible if ADT commenced within 120 days before randomization, they have not started docetaxel chemotherapy yet, and there was no evidence of clinical, radiological or biochemical progression after ADT.

9. Patients receiving ADT in the adjuvant and/or neoadjuvant setting for less than 30 months of therapy, AND the effect of the last depot injection had expired at least 12 months prior to documentation of metastatic disease, AND

• They had no evidence of disease (PSA < 0.2 ng/dL) after prostatectomy plus hormonal therapy, or
• PSA was < 0.5 ng/dL after completing radiation therapy plus adjuvant or neoadjuvant hormonal therapy, and had not doubled above nadir in at least 12 months.

10. Patients must have adequate organ function within 4 weeks prior to randomization and

evidenced by:

• Absolute Neutrophil Count > 1500/mm 3
• Platelet count > 100,000/mm 3
• Creatinine clearance (CrCl)> 30 mL/min calculated at screening using the Cockcroft- Gault formula: Creatinine clearance for mule (mL/min) = (140- age in years)(body weight in kg)/[72x(serum creatinine in mg/dl).
• Total bilirubin < 1.5 ULN (< 3.0 mg/dl in patients with Gilbert´s Syndrome).
• Prothrombin time or INR and PTT < 1.5 x ULN, except if on therapeutic anti- coagulation in which case the patient can be enrolled if stable and anti-coagulation levels are appropriate for their condition per good clinical practice.
• ALT and AST < or = 3 x ULN (or < or = 5 if liver metastases)

11. At least 4 weeks should have passed after major surgery prior to randomization, and the patient should be recovered from all side effects and complications.

12. Men who are sexually active with WOCBP must agree to follow instructions for methods of contraception for the duration of treatment with study drug plus 5 half-lives of study drug plus 90 days (duration of sperm turnover) for a total of 31 weeks post-treatment completion.

Exclusion Criteria:

1. Patients are not eligible if the PSA has risen from its lowest point, between the beginning of androgen deprivation therapy and the date of randomization, and met criteria for progression as defined in the protocol.

2. Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, PROSTVAC, Sipuleucel-T or any previous immunotherapy or vaccines for cancer.

3. Prior chemotherapy in the adjuvant or neoadjuvant setting.

4. Unable to receive docetaxel at full doses at investigator criteria.

5. Peripheral neuropathy grade > 1.

6. All toxicities attributed to prior anti-cancer therapy other than neuropathy, alopecia or fatigue must have resolved to Grade 1 (NCI CTCAE version 4) or baseline before administration of study drug. Subjects with toxicities attributed to prior surgery or radiotherapy, which are not expected to resolve and result in long-term lasting sequelae, are permitted to enrol.

7. History of hypersensitivity reaction to Docetaxel®, other drugs formulated with polysorbate 80, or monoclonal antibodies.

8. Prior hormone therapy or immunotherapy in the metastatic setting.

9. Prior palliative radiation therapy within 30 days of starting docetaxel.

10. Known acute or chronic HIV, Hepatitis B, or Hepatitis C. Past Hepatitis B infection with no signs of activity later, are allowed

11. Active brain metastases or leptomeningeal metastases, except if they have been treated and there is a magnetic resonance imaging (or CT scan if MRI were contraindicated) showing no evidence of progression for at least 4 weeks after the treatment

12. Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days previous to randomization. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.

13. Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are allowed.

14. Active cardiac disease defined as active angina, symptomatic congestive heart failure, or myocardial infarction within the previous six months

15. History of malignancy in the past 5 years except for basal cell and squamous cell carcinoma of the skin and non-muscle-invasive bladder cancer. Other more malignancies considered to have a low potential to progress may be enrolled if approved by study chair.

16. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.

17. Participation in another clinical trial within 30 days prior to randomization.

Related Conditions & MeSH terms

• Hypersensitivity
• Metastatic Hormone-sensitive Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Ipilimumab 5 MG/ML
Ipilimumab will be administered on day 1 of each cycle every 3 weeks. In arm 3, ipilimumab should be started at least 2 weeks but no later than 120 days after surgical castration or the first dose of LHRH analogue. Patients should receive 2 doses of ipilimumab (6 weeks). It will be followed, 3 weeks later, by 3 cycles of docetaxel and by 2 additional doses of ipilimumab and 3 more cycles of docetaxel. Four weeks later, Nivolumab will be administered on day 1 every 2 weeks until a maximum of 24 doses (48 weeks)
• Nivolumab 10 MG/ML
Nivolumab will be administered every 2 weeks, until clinical progression or a maximum of 24 doses. Nivolumab should be started 4 weeks after the last dose of docetaxel, providing all the adverse effects have recovered, as if a new cycle of docetaxel were to be administered
• Docetaxel
Docetaxel should be given on day 1 every 21 days, for up to 6 cycles (1 cycle = 21 days). Docetaxel should be started within 7 working days from the date of randomization in the arm 1 and 2. In arm 3, docetaxel will be given 3 weeks after the last dose of the previous treatment, providing all the side effects are grade =1.
• ADT (androgen deprivation therapy)
Androgen deprivation therapy per the standard of care

Locations

Country	Name	City	State
Spain	Hospital Clínic de Barcelona	Barcelona
Spain	Hospital Del Mar	Barcelona
Spain	Hospital Universitari Vall D'Hebron	Barcelona
Spain	Hospital de Basurto	Bilbao	Vizcaya
Spain	Hospital Universitario de Burgos	Burgos
Spain	Hospital San Pedro de Alcántara	Cáceres
Spain	Hospital General de Ciudad Real	Ciudad Real
Spain	Hospital General, Materno E Infantil Reina	Córdoba	Cordoba
Spain	Hospital Universitari de Girona Dr. Josep Trueta	Girona
Spain	Hestia Duran I Reynals	Hospitalet de Llobregat	Barcelona
Spain	Hospital Universitario Lucus Augusti	Lugo
Spain	Hospital Clínico San Carlos	Madrid
Spain	Hospital General Universitario Gregorio Marañón	Madrid
Spain	Hospital Ramón Y Cajal	Madrid
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	Hospital Universitario Puerta de Hierro Majadahonda	Majadahonda	Madrid
Spain	Hospital Sant Joan de Deu (Althaia Manresa)	Manresa	Barcelona
Spain	Hospital Universitario Central de Asturias	Oviedo	Asturias
Spain	Hospital Son Llatzer	Palma De Mallorca	Islas Baleares
Spain	Complejo Hospitalario de Navarra	Pamplona	Navarra
Spain	Hospital de Sabadell	Sabadell	Barcelona
Spain	Hospital Universitario Infanta Sofía	San Sebastián De Los Reyes	Madrid
Spain	Hospital Nuestra Señora de Valme	Sevilla
Spain	Hospital Virgen Del Rocío	Sevilla
Spain	Hospital Virgen Macarena	Sevilla
Spain	Hospital Virgen de La Salud	Toledo
Spain	Consorcio Hospital General Universitario de Valencia	Valencia
Spain	Fundación Instituto Valenciano de Oncología	Valencia
Spain	Hospital Arnau de Vilanova	Valencia	Valenci
Spain	Hospital Universitario Alvaro Cunqueiro	Vigo

Sponsors (3)

Lead Sponsor	Collaborator
Spanish Oncology Genito-Urinary Group	Bristol-Myers Squibb, Syntax for Science, S.L

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival	Overall Survival	through study completion, an average of 2 years
Secondary	PSA response		through study completion, an average of 2 years
Secondary	PSA progression-free survival (PSA-PFS)		through study completion, an average of 2 years
Secondary	Radiological progression-free survival (rPFS)		through study completion, an average of 2 years
Secondary	Clinical progression-free survival (cPFS)		through study completion, an average of 2 years
Secondary	Time to castration resistant prostate cancer (TCRPC)		through study completion, an average of 2 years
Secondary	Immune radiological progression-free survival (irPFS)		through study completion, an average of 2 years
Secondary	Immune clinical progression-free survival (icPFS)		through study completion, an average of 2 years
Secondary	Time to immune castration resistant prostate cancer (TiCRPC)		through study completion, an average of 2 years
Secondary	Symptomatic skeletal-related event free survival (SSREFS)		through study completion, an average of 2 years
Secondary	Toxicity of each of the treatment arms by assessing Adverse Events		through study completion, an average of 2 years
Secondary	Quality of life (QOL)	EQ-5D Questionnaire	through study completion, an average of 2 years
Secondary	Quality of life (QOL)	FACT-P Questionnaire	through study completion, an average of 2 years
Secondary	Quality of life (QOL)	BPI Questionnaire	through study completion, an average of 2 years